AI for Commercial

AI-Enhanced Key Account Management in Pharma

ANG Associates
Life Sciences & AI Consulting

Sep 2025 5 min read

The Widening Gap Between Account Complexity and Account Teams

A pharmaceutical key account manager (KAM) calling on a major hospital network or a national payer is rarely negotiating with a single decision maker anymore. Deloitte's November 2024 survey of 100 commercial leaders across 77 life sciences companies found that 56% believe the entire commercial function needs to change significantly or transform fully, yet only 30% felt well prepared for the shift, with 76% still hindered by siloed and outdated data infrastructure, according to Deloitte's "Future of pharma's commercial model" report. Guidehouse makes a related point in its analysis of pharma KAM: many organizations have relabeled the traditional sales function without changing how it operates, even as stakeholders now expect pharma to act as a "system integrator" spanning government, public, and private payers, providers across sites of care, and intermediaries such as pharmacy benefit managers and group purchasing organizations. A single strategic account can involve a formulary committee, a value analysis committee, a health system's C-suite, and a payer's utilization management team, each with its own priorities and timeline.

What AI Dashboards Actually Bring to the KAM Desk

The commercial CRM and data vendors serving pharma have built specifically toward this complexity. Veeva's Link Key Accounts product, for example, aggregates formulary committee membership, decision maker networks, regulatory documents, business partnerships, quality measures, and disease-specific insights derived from patient diagnosis data into curated profiles covering major U.S. hospital and payer accounts, with the stated goal of helping teams identify previously unknown formulary decision makers and reduce time spent on manual research. Veeva's Vault CRM suite, used by more than 180 customers including Regeneron, Biogen, Novo Nordisk, and GSK, has extended this with an "Agentic Call Report" feature that turns field call notes into structured commercial insight rather than a static log. Salesforce has taken a parallel path with its Life Sciences Cloud, layering AI-driven assistants and its Agentforce tools on top of account data to support what it frames as more personalized, compliant engagement with health system and payer stakeholders. In practice, these tools do not replace the KAM's relationship-building work; they consolidate what used to live in spreadsheets, call notes, and individual reps' memories into a single view of formulary status, contract terms, and the account's stakeholder map, so the KAM spends more of a limited number of account interactions on strategy rather than reconciliation.

What the Data Actually Shows

The evidence for AI-enabled account intelligence is strongest where it addresses concrete, quantifiable friction rather than vague productivity claims. A 2025 analysis in Pharmaceutical Commerce noted that gross-to-net reductions, the rebates and discounts manufacturers pay to payers and PBMs, totaled roughly $356 billion in 2024, more than half of gross U.S. pharmaceutical revenue, and estimated that 2 to 3% of rebate value is routinely compromised by formulary leakage, meaning a payer fails to honor a contracted formulary position. For a manufacturer paying $500 million a year in rebates, that gap represents $10 to 15 million in recoverable value, a problem the article argues is well suited to AI agents that can cross-reference claims and formulary data at a scale manual reconciliation cannot match.

"56% of survey respondents said the entire commercial function needs to change significantly or transform fully."

Separately, a Forrester study commissioned for Salesforce's health and life sciences customers found that 86% of decision makers in the sector believe the ability to effectively use technology, data, and AI will define competitive success over the next five years, while only 60% felt their organizations were adopting AI quickly enough and 49% cited fragmented or inaccessible data as a direct roadblock. Read together, these findings point to the same conclusion from three independent sources: the data pharma commercial teams need for strategic accounts already exists, but it is scattered across claims systems, CRM records, and payer contracts in ways that slow account teams down and, in cases like formulary leakage, cost real money.

Deloitte: 56% of commercial leaders say the function needs significant or full transformation; 76% cite siloed, outdated data infrastructure as a barrier.
Pharmaceutical Commerce: an estimated 2-3% of rebate value is lost to formulary leakage, worth $10-15 million annually for a $500 million rebate book.
Forrester (via Salesforce): 86% of health and life sciences leaders see AI and data capability as decisive for future success, but 49% are blocked by fragmented data.

Where a Delivery Partner Fits

None of this changes the fact that consolidating formulary, stakeholder, and contract data into a usable KAM dashboard is a validated system change in a regulated environment, not a marketing project. It requires an honest AI strategy for what the data can and cannot support, a CRM and analytics implementation (Veeva, Salesforce, or an equivalent platform) configured to each account structure, GxP-aware validation of any system that touches regulated commercial or medical data, and an Agile or SAFe delivery approach that can iterate with commercial stakeholders instead of shipping a fixed dashboard nobody adjusts. This is the intersection where a firm like ANG Associates works: helping pharma and life sciences commercial teams move from scattered account data to a validated, adopted analytics capability, without overpromising what an AI layer can do for a relationship that still depends on the KAM in the room.

Sources

key account managementpharma AIformulary analyticslife sciences CRMmarket access

Interested in this topic?

Let's discuss how we can apply these approaches to your organization.